Literature DB >> 21172674

TB and HIV in children - advances in prevention and management.

B J Marais1, H Rabie, M F Cotton.   

Abstract

The human immunodeficiency virus (HIV) epidemic has had a major impact on the age and gender profile of adult tuberculosis (TB) patients, resulting in increased exposure of HIV-infected and uninfected children at a very young age. Young and/or HIV-infected children are extremely vulnerable to develop severe forms of TB following recent exposure and infection. There is an urgent need to implement safe and pragmatic strategies to prevent TB in children, especially in TB endemic areas where they suffer the greatest burden of disease. The management of TB in HIV-infected children poses multiple challenges, but recent advances in the implementation of prevention of mother to child transmission (PMTCT) strategies and HIV care of infants offer hope. These include HIV testing and access to PMTCT for all pregnant women, routine testing of all HIV exposed infants and rapid initiation of antiretroviral treatment irrespective of clinical or immunological disease staging. In addition, careful scrutiny for TB exposure should occur at every health care visit, with provision of isoniazid preventive therapy (IPT) following each documented exposure event. Knowing the HIV infection status of child TB suspects is essential to optimize case management. Although multiple difficulties remain, recent advances demonstrate that the management of children with TB and/or HIV can be vastly improved by well focused interventions using readily available resources. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21172674     DOI: 10.1016/j.prrv.2010.09.002

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  15 in total

1.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 2.  Pediatric drug-resistant tuberculosis: a global perspective: a global perspective.

Authors:  Gary Reubenson
Journal:  Paediatr Drugs       Date:  2011-12-01       Impact factor: 3.022

3.  Dilemma of managing asymptomatic children referred with 'culture-confirmed' drug-resistant tuberculosis.

Authors:  Marian Loveday; Babu Sunkari; Ben J Marais; Iqbal Master; James C M Brust
Journal:  Arch Dis Child       Date:  2016-04-04       Impact factor: 3.791

Review 4.  PEPFAR support for the scaling up of collaborative TB/HIV activities.

Authors:  Andrea A Howard; Michel Gasana; Haileyesus Getahun; Anthony Harries; Stephen D Lawn; Bess Miller; Lisa Nelson; Joseph Sitienei; William L Coggin
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

Review 5.  When to start antiretroviral therapy during tuberculosis treatment?

Authors:  Kogieleum Naidoo; Cheryl Baxter; Salim S Abdool Karim
Journal:  Curr Opin Infect Dis       Date:  2013-02       Impact factor: 4.915

6.  Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting.

Authors:  Novel N Chegou; Gillian F Black; Andre G Loxton; Kim Stanley; Paulin N Essone; Michel R Klein; Shreemanta K Parida; Stefan H E Kaufmann; T Mark Doherty; Annemieke H Friggen; Kees L Franken; Tom H Ottenhoff; Gerhard Walzl
Journal:  BMC Infect Dis       Date:  2012-01-20       Impact factor: 3.090

7.  Recent developments in the epidemiology and management of tuberculosis - new solutions to old problems?

Authors:  Wolfgang M Thaiss; Cornelius C Thaiss; Christoph A Thaiss
Journal:  Infect Drug Resist       Date:  2012-01-09       Impact factor: 4.003

8.  Utility of host markers detected in Quantiferon supernatants for the diagnosis of tuberculosis in children in a high-burden setting.

Authors:  Novel N Chegou; Anne K Detjen; Lani Thiart; Elisabetta Walters; Anna M Mandalakas; Anneke C Hesseling; Gerhard Walzl
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

Review 9.  Towards early inclusion of children in tuberculosis drugs trials: a consensus statement.

Authors:  Sharon Nachman; Amina Ahmed; Farhana Amanullah; Mercedes C Becerra; Radu Botgros; Grania Brigden; Renee Browning; Elizabeth Gardiner; Richard Hafner; Anneke Hesseling; Cleotilde How; Patrick Jean-Philippe; Erica Lessem; Mamodikoe Makhene; Nontombi Mbelle; Ben Marais; Helen McIlleron; David F McNeeley; Carl Mendel; Stephen Murray; Eileen Navarro; E Gloria Anyalechi; Ariel R Porcalla; Clydette Powell; Mair Powell; Mona Rigaud; Vanessa Rouzier; Pearl Samson; H Simon Schaaf; Seema Shah; Jeff Starke; Soumya Swaminathan; Eric Wobudeya; Carol Worrell
Journal:  Lancet Infect Dis       Date:  2015-05-06       Impact factor: 25.071

10.  Decentralised paediatric HIV care in Ethiopia: a comparison between outcomes of patients managed in health centres and in a hospital clinic.

Authors:  Oskar Hagströmer; Lars Lundstedt; Taye Tolera Balcha; Per Björkman
Journal:  Glob Health Action       Date:  2013-11-11       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.